Contact
Contact

SECOND QUARTER 2026 UPDATES

A Transformative Quarter Unlocking Value & Returning Capital to Shareholders With a Focus on Innovation, Clinical Progress & Long-Term Growth The second quarter of 2026 marked a defining milestone for Cumberland Pharmaceuticals. With the successful completion of our Strategic Transaction, we entered a new chapter as an innovation-focused biopharmaceutical company dedicated to advancing new medicines […]

FIRST QUARTER 2026 UPDATE

  We are off to a strong start in 2026, building on the momentum generated over the past year while entering into a transformational agreement designed to position Cumberland for its next phase of growth. We recently announced a Strategic Transaction with Apotex Inc. to integrate our branded U.S. commercial businesses. Under the terms of […]

THIRD QUARTER 2025 UPDATES, INCLUDING NEW PRODUCT ADDITION AND INTERNATIONAL EXPANSION

We’re thrilled to share several exciting developments from the third quarter of 2025, including the arrival of a new addition to our commercial product portfolio – Talicia®, a leading triple therapy for the treatment of Helicobacter pylori infections: Talicia features include three key advantages – high eradication rates at >90%, simplicity of an all in […]

SECOND QUARTER 2025 UPDATES INCLUDE NEW CLINICAL DATA & FINANCIAL MOMENTUM

We enjoyed a strong first half of the year! During the second quarter, our momentum continued, as we advanced our mission of working together to deliver favorable commercial and clinical development results. During the quarter we remained dedicated to advancing our mission of working together to provide unique products that improve the quality of patient […]

FIRST QUARTER 2025 UPDATES, INCLUDING BREAKTHROUGH PHASE 2 DMD STUDY RESULTS

Our approved brands remain a key driver of performance, while expanded international partnerships and steady advancement in our clinical development programs further strengthen our position. We are also evaluating select acquisition opportunities that align with our strategic objectives. As we look ahead, we remain committed to executing our growth strategy and delivering long-term value. We […]

EARLY 2025 MILESTONES

Cumberland’s business strategy has been to acquire and commercialize a portfolio of branded pharmaceuticals that we can grow through our dedicated sales organization domestically and through our partners internationally. We’ve also built an internal development capability, which enables us to develop and register new medicines, establishing a long-term pipeline for our business. We recently reported […]

November 2024 Updates, Highlighting Key Clinical and Business Developments

We are pleased to report several significant milestones that reinforce our mission of working together to provide unique products that improve the quality of patient care. Our latest updates include important research findings, growing Medicaid coverage and expanded product access. In October, we announced new real-world outcomes research comparing Caldolor® to its key competitor – […]

Second Quarter 2024 Updates, Including Double-Digit Revenue Growth

We were pleased to report that Cumberland delivered a strong financial performance for the second quarter. Our line of FDA-approved brands delivered just under $10 million in net revenues, which represented 16% in sequential growth from the first quarter of the year. During the quarter we remained dedicated to advancing our mission of working together […]

First Quarter 2024 Updates, Including a Special Report for Our Caldolor® Product

Overall, the first quarter proved to be a productive start to the year. Our Cumberland team remains dedicated to our mission of working together to provide unique products that improve the quality of patient care. During the quarter, we shared a number of exciting company updates, including several growth opportunities for our portfolio of brands. […]